Peter N. Morcos

1.5k total citations
37 papers, 597 citations indexed

About

Peter N. Morcos is a scholar working on Oncology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Peter N. Morcos has authored 37 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Genetics and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Peter N. Morcos's work include CAR-T cell therapy research (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Peter N. Morcos is often cited by papers focused on CAR-T cell therapy research (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Peter N. Morcos collaborates with scholars based in United States, Switzerland and United Kingdom. Peter N. Morcos's co-authors include Patrick F. Smith, Isabel Nájera, Brett Ritchie, Nancy S. Shulman, Mark Laughlin, Linda Baher, Peter Angus, M. Michelle Berrey, Stuart K. Roberts and David Ipe and has published in prestigious journals such as The Lancet, Blood and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Peter N. Morcos

34 papers receiving 582 citations

Peers

Countries citing papers authored by Peter N. Morcos

Since Specialization

Citations

This map shows the geographic impact of Peter N. Morcos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter N. Morcos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter N. Morcos more than expected).

Fields of papers citing papers by Peter N. Morcos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter N. Morcos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter N. Morcos. The network helps show where Peter N. Morcos may publish in the future.

Co-authorship network of co-authors of Peter N. Morcos

This figure shows the co-authorship network connecting the top 25 collaborators of Peter N. Morcos. A scholar is included among the top collaborators of Peter N. Morcos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter N. Morcos. Peter N. Morcos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis 2025 ·Clinical and Translational Science ·(unknown), Libo Sun, Fei Huang, (unknown), Robert Kleiman, (unknown), (unknown), Ying Wan, Tymara Berry, Faye Feller, Peter N. Morcos	0
2	Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors 2025 ·Cancer Research Communications ·Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, (unknown), (unknown), (unknown), (unknown), Florian Hiemeyer, Peter N. Morcos, (unknown), Barrett H. Childs, Aaron R. Hansen	1
3	Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen 2024 ·Clinical Pharmacology & Therapeutics ·Peter N. Morcos, Jonathan Moss, (unknown), Florian Hiemeyer, Barrett H. Childs, Dirk Garmann	2
4	Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science 2024 ·Clinical and Translational Science ·(unknown), Fei Huang, (unknown), (unknown), (unknown), Ying Wan, Libo Sun, Tymara Berry, Faye Feller, Peter N. Morcos	12
5	Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor 2024 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), Fei Huang, (unknown), Ying Wan, Libo Sun, Tymara Berry, (unknown), Faye Feller, Peter N. Morcos	4
6	Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors 2023 ·Clinical and Translational Science ·Peter N. Morcos, (unknown), Rolf Burghaus, Jonathan Moss, Adam Lloyd, Barrett H. Childs, Margaret E. Macy, Joel M. Reid, John Chung, Dirk Garmann	3
7	Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Peter N. Morcos, Jonathan Moss, Rupert Austin, Florian Hiemeyer, Pier Luigi Zinzani, (unknown), (unknown), Barrett H. Childs, Dirk Garmann	3
8	Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs 2020 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), Peter N. Morcos, François Mercier, Barbara J. Brennan	1
9	Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing 2020 ·Blood ·Nassim Djebli, Peter N. Morcos, (unknown), Elena Guerini, Nicole A. Kratochwil, (unknown), Eginhard Schick, Antonia Kwan, Kathryn Humphrey, Linda Lundberg, David Carlile	14
10	Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 2019 ·Blood ·Nassim Djebli, (unknown), (unknown), François Mercier, Nicole A. Kratochwil, Ann-Marie E Bröske, Natalie Dimier, Cristiano Ferlini, Tom Moore, Maja Weisser, Peter N. Morcos	7
11	Rituximab dosing in hematological malignancies: an old question, revisited 2019 ·Cancer Chemotherapy and Pharmacology ·Peter N. Morcos, (unknown), Nancy Valente, Donald E. Mager	2
12	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial 2019 ·Blood ·Franck Morschhauser, Carmelo Carlo‐Stella, Fritz Offner, Gilles Salles, Martin Hutchings, Gloria Iacoboni, Anna Sureda, Michael Crump, Joaquín Martínez‐López, (unknown), Peter N. Morcos, Cristiano Ferlini, K. Abiraj, Ann-Marie E Bröske, Marina Bacac, Natalie Dimier, Tom Moore, Maja Weisser, Michael Dickinson	24
13	CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial 2019 ·Blood ·Ann-Marie E Bröske, Ian James, Anton Belousov, Enrique Gómez Alcaide, Marta Cañamero, Chia-Huey Ooi, Nils Grabole, (unknown), Koorosh Korfi, Nicole A. Kratochwil, Peter N. Morcos, Cristiano Ferlini, (unknown), Natalie Dimier, Tom Moore, Marina Bacac, Maja Weisser, Michael Dickinson	5
14	CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial 2018 ·Blood ·Martin Hutchings, Gloria Iacoboni, Franck Morschhauser, Fritz Offner, Anna Sureda, Gilles Salles, Carmelo Carlo‐Stella, Joaquín Martínez‐López, (unknown), Peter N. Morcos, (unknown), Cristiano Ferlini, Marina Bacac, (unknown), Natalie Dimier, Tom Moore, Maja Weisser, Michael Dickinson	25
15	Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients 2015 ·Drugs in R&D ·Marta Boffito, Akil Jackson, Anton Pozniak, (unknown), Rohit Kulkarni, (unknown), Indravadan H. Patel, Peter N. Morcos	4
16	Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir 2014 ·Clinical Pharmacokinetics ·Barbara J. Brennan, Agnès Poirier, (unknown), Peter N. Morcos, Petra Goelzer, Renée Portmann, (unknown), Christoph Funk, Patrick F. Smith	12
17	Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20 2013 ·International Journal of Clinical Pharmacology and Therapeutics ·Peter N. Morcos, Xiaoping Zhang, Christine McIntyre, Beate Bittner, Lucy Rowell, Zubair Hussain	19
18	Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin 2013 ·Clinical Pharmacokinetics ·Barbara J. Brennan, (unknown), Peter N. Morcos, Mercidita T. Navarro, (unknown), Petra Goelzer, Paul Weigl, Patrick F. Smith	15
19	Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial 2010 ·The Lancet ·Edward Gane, Stuart K. Roberts, (unknown), Peter Angus, Brett Ritchie, Rob Elston, David Ipe, Peter N. Morcos, Linda Baher, Isabel Nájera, Tom Chu, Uri Lopatin, M. Michelle Berrey, William Bradford, Mark Laughlin, Nancy S. Shulman, Patrick F. Smith	240
20	CLINICAL STUDY: Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate‐dependent HIV‐negative patients on stable methadone maintenance therapy 2009 ·Addiction Biology ·Candice Jamois, Patrick F. Smith, (unknown), Myriam Riek, (unknown), Christophe Schmitt, Peter N. Morcos, Xiaoping Zhang	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact